Legato Capital Management LLC
Position in ELVN — Enliven Therapeutics, Inc.
CIK 1442641
San Francisco, CA
Position in ELVN
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$3,287,026
+$2,065,006 QoQ
Shares Held
64,769
+107.8% QoQ
Ownership
0.088%
of shares outstanding
% of Portfolio
0.27%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
4 quarters on record
Common Shares in ELVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Legato Capital Management LLC holds $78,908,724 across 38 Biotechnology names. ELVN ranks #8 (4.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
58,512 | $6,849,999 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
33,042 | $6,188,105 | |
| 3 | TVTX |
Travere Therapeutics, Inc.
|
87,833 | $4,989,792 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
15,569 | $4,921,205 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
18,644 | $4,563,491 | |
| 6 | PVLA |
Palvella Therapeutics, Inc.
|
23,490 | $3,589,741 | |
| 7 | CORT |
Corcept Therapeutics Inc
|
41,186 | $3,581,122 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
This page
|
64,769 | $3,287,026 |
All Filings in ELVN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,287,026 | 64,769 | Shares | Other | 2026-08-06 | |
| 2026-03-31 | $1,222,020 | 31,174 | Shares | Other | 2026-05-14 | |
| 2024-12-31 | $303,570 | 13,492 | Shares | Other | 2025-01-29 | |
| 2024-09-30 | $372,424 | 14,582 | Shares | Other | 2024-11-07 | |
| No filing history on record for this holder in this stock. | ||||||